AMENDMENTS TO THE CLAIMS

Please amend the claims as shown in the listing of the claims below. The listing of claims replaces all prior versions and listings of claim in the application.

Listing of Claims

Claims 1 to 25 (Cancelled)

26. (New) A method of screening for candidate compounds to identify G-protein coupled receptor polypeptide modulators, comprising:

(a) contacting a test compound with a cell or tissue comprising an expression vector capable of expressing a polypeptide comprising an amino acid sequence as set forth in SEQ ID NO:2, or encoded by ATCC deposit PTA-2966, under conditions in which said polypeptide is expressed; and

(b) selecting as candidate modulating compounds those test compounds that modulate activity of the G-protein coupled receptor polypeptide.

27. (New) The method according to claim 26 wherein said cells are CHO cells.

28. (New) The method according to claim 27 wherein said cells comprise a vector comprising the coding sequence of the beta lactamase gene under the control of one or more NFAT response elements.

29. (New) The method according to claim 28 [TRUE?] wherein said cells further comprise a vector comprising the coding sequence of G alpha 15 under conditions wherein G alpha 15 is expressed.

30. (New) The method according to claim 27 wherein said cells are HEK cells.

31. (New) The method according to claim 30 wherein said cells express a polypeptide comprising an amino acid sequence set forth in SEQ ID NO:2, an amino acid sequence encoded by ATCC deposit PTA-2966, or beta lactamase, at either high or low levels of expression relative to the expression of a reference polypeptide.

32. (New) The method according to claim 30 wherein said cells further comprise a vector comprising the coding sequence of the polypeptide provided as SEQ ID NO:103.

33. (New) The method according to claim 30 wherein said candidate compound is selected from the group consisting of: a small molecule; a peptide; and an antisense molecule.

34. (New) The method according to claim 33 wherein said candidate compound is an agonist.

35. (New) The method according to claim 33 wherein said candidate compound is an antagonist.

36. (New) The method according to claim 26 wherein said candidate compound is useful for treating anxiolytic disorders.

37. (New) The method according to claim 26 wherein said candidate compound is useful for treating caudate nucleus disorders.

38. (New) The method according to claim 26 wherein said G-protein coupled receptor is HGPRBMY 8.